[HTML][HTML] The role of microRNAs expression in laryngeal cancer
X Yu, Z Li - Oncotarget, 2015 - ncbi.nlm.nih.gov
MicroRNAs (miRs, miRs) is a class of small non-coding RNAs, which posttranscriptionally
regulate gene expression. Deregulated miRs are frequently obseved in patients with …
regulate gene expression. Deregulated miRs are frequently obseved in patients with …
miRNAs in the pathogenesis of systemic lupus erythematosus
MicroRNAs (miRNAs) were first discovered as regulatory RNAs that controlled the timing of
the larval development of Caenorhabditis elegans. Since then, nearly 30,000 mature miRNA …
the larval development of Caenorhabditis elegans. Since then, nearly 30,000 mature miRNA …
Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway
X Feng, J Jiang, S Shi, H Xie… - … journal of oncology, 2016 - spandidos-publications.com
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is considered as a
promising anticancer agent, it induced apoptosis in cancer cells selectively without …
promising anticancer agent, it induced apoptosis in cancer cells selectively without …
Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma
Z Zhang, H Meng, N Wang, L Liang, L Liu, S Lu… - Diagnostic …, 2014 - Springer
Background Hepatocellular carcinoma (HCC) is regarded as one of the most common
malignancies and among the leading causes of cancer death among the whole world. The …
malignancies and among the leading causes of cancer death among the whole world. The …
NEAT1 contributes to ox‐LDL‐induced inflammation and oxidative stress in macrophages through inhibiting miR‐128
DD Chen, LL Hui, XC Zhang… - Journal of cellular …, 2019 - Wiley Online Library
Long noncoding RNAs (lncRNA) have been recognized as significant regulators in the
progression of atherosclerosis (AS). Oxidized low‐density lipoprotein (ox‐LDL) can induce …
progression of atherosclerosis (AS). Oxidized low‐density lipoprotein (ox‐LDL) can induce …
MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2in laryngeal carcinoma
Y Tian, S Fu, GB Qiu, ZM Xu, N Liu, XW Zhang, S Chen… - BMC cancer, 2014 - Springer
Background miRNA-27a has been confirmed as an important regulator in carcinogenesis
and other pathological processes. Whether and how it plays a role in the laryngeal …
and other pathological processes. Whether and how it plays a role in the laryngeal …
Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway
Z Han, X Zhou, S Li, Y Qin, Y Chen… - Oncology …, 2017 - spandidos-publications.com
Epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR-TKIs) have
become first-line drugs used for non-small cell lung cancer (NSCLC) treatment. However …
become first-line drugs used for non-small cell lung cancer (NSCLC) treatment. However …
High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma
Y Li, Y Jiao, Z Fu, Z Luo, J Su, Y Li - Cancer management and …, 2019 - Taylor & Francis
Purpose: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in
the clinic all over the world, which has become a public health challenge. The T/N/M staging …
the clinic all over the world, which has become a public health challenge. The T/N/M staging …
Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN
Y Zhu, H Tang, L Zhang, L Gong, G Wu… - Cancer management …, 2019 - Taylor & Francis
Background TNF-related apoptosis-inducing ligand (TRAIL) functions as a selective
apoptosis-inducing ligand in cancer cells with normal cells remaining unaffected; however …
apoptosis-inducing ligand in cancer cells with normal cells remaining unaffected; however …
[HTML][HTML] MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway
J Jiang, X Feng, W Zhou, Y Wu, Y Yang - Oncotarget, 2016 - ncbi.nlm.nih.gov
Gefitinib is a first line anti-tumor drug used for the treatment of patients with non-small cell
lung cancer (NSCLC) harboring EGFR mutations. However, the drug resistance to gefitinib …
lung cancer (NSCLC) harboring EGFR mutations. However, the drug resistance to gefitinib …